Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 71
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
A developmental constraint model of cancer cell states and tumor heterogeneity
Ayushi Patel, Itai Yanai
Cell (2024) Vol. 187, Iss. 12, pp. 2907-2918
Closed Access | Times Cited: 26
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3304-3304
Open Access | Times Cited: 15
Cancer plasticity in therapy resistance: Mechanisms and novel strategies
Xing Niu, Wenjing Liu, Zhang Yinling, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101114-101114
Closed Access | Times Cited: 15
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 11
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
Rodrigo Romero, Tinyi Chu, Tania J. González-Robles, et al.
Nature Cancer (2024) Vol. 5, Iss. 11, pp. 1641-1659
Open Access | Times Cited: 10
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy
Brian S. Henick, Alison Taylor, Hiroshi Nakagawa, et al.
Cancer Cell (2025) Vol. 43, Iss. 2, pp. 178-194
Closed Access | Times Cited: 1
TET2–STAT3–CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition
Yun Xue, Y. B. Chen, Sijia Sun, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 7
Open Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Mesenchymal stromal cells promote the formation of lung cancer organoids via Kindlin-2
Zhilin Sui, Xianxian Wu, Jiaxin Wang, et al.
Stem Cell Research & Therapy (2025) Vol. 16, Iss. 1
Open Access
Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial
Marcelo V. Negrão, Alvaro G. Paula, David Molkentine, et al.
Clinical Cancer Research (2025)
Open Access
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Gary Middleton, Helen L. Robbins, Peter Fletcher, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
KLF4 promotes a KRT13+ hillock-like state in squamous lung cancer
Luke Izzo, Tony Reyes, Srijan Meesala, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
DelaySSA: stochastic simulation of biochemical systems and gene regulatory networks with or without time delays
Ziyan Jin, Xinyi Zhou, Zhaoyuan Fang
PLoS Computational Biology (2025) Vol. 21, Iss. 4, pp. e1012919-e1012919
Open Access
Lysosomes: guardians and healers within cells- multifaceted perspective and outlook from injury repair to disease treatment
Jichao Bi, Yue‐Li Sun, Meihua Guo, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy
Yue Shen, Jie-Qi Chen, Xiangping Li
Genes & Diseases (2024) Vol. 12, Iss. 3, pp. 101374-101374
Open Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer
Mehran Karimzadeh, Amir Momen-Roknabadi, Taylor B. Cavazos, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Jinshou Yang, Feihan Zhou, Xiyuan Luo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review
Fan Zhang, Banglu Wang, Menghuan Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Insights into how adeno-squamous transition drives KRAS inhibitor resistance
Feng Hu, Piro Lito
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 330-332
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top